Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.48 |
| ▸ | TTR | P02766 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.45 |
| ▸ | EGFR | P00533 | 1/20 | 0.45 |
| ▸ | APP | P05067 | 1/20 | 0.44 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL435484 | 0.87 | F2 (0.49) | BACE1MEN1KMT2AAPP | |
| SCHEMBL3208961 | 0.87 | ALOX5 (0.55) | BACE1TTRMEN1KMT2AKDM4E | |
| SCHEMBL20152947 | 0.87 | ALOX5 (0.49) | BACE1TTRMEN1KMT2AKDM4E | |
| SCHEMBL6035879 | 0.86 | CYP4F2 (0.50) | TTRMEN1KMT2AKDM4EALDH1A1 | |
| SCHEMBL64208 | 0.84 | MTNR1A (0.61) | MEN1KMT2AHSD17B10 | |
| SCHEMBL6036250 | 0.83 | EGFR (0.55) | BACE1TTRMEN1KMT2AKDM4E | |
| SCHEMBL16294051 | 0.83 | KDM4E (0.53) | MEN1KMT2AKDM4EALDH1A1HSD17B10 | |
| SCHEMBL8550870 | 0.83 | ADRA1A (0.45) | ALDH1A1PDE4D | |
| SCHEMBL4616924 | 0.82 | ALDH1A1 (0.43) | KMT2AKDM4EALDH1A1HSD17B10EGFR | |
| SCHEMBL3659525 | 0.81 | ALDH1A1 (0.43) | MEN1KMT2AKDM4EALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7371777-B2 | Cyclic compound and PPAR agonist | EISAI CO., LTD. (JP) | 2008-05-13 | — | — | US | disclosed |
| US-20050014833-A1 | Cyclic compound and ppar agonist | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2005-01-20 | — | — | US | disclosed |
| EP-1452521-A1 | CYCLIC COMPOUND AND PPAR AGONIST | Eisai Co., Ltd. (JP) | 2004-09-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050014833-A1 | Cyclic compound and ppar agonist | PPARA, PPARG, PPARD | BACE1 3294/4885TTR 3976/4885MEN1 4855/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.